WO2008050162A1 - Process for the preparation of desloratadine adduct formed with carbon dioxide - Google Patents

Process for the preparation of desloratadine adduct formed with carbon dioxide Download PDF

Info

Publication number
WO2008050162A1
WO2008050162A1 PCT/HU2007/000096 HU2007000096W WO2008050162A1 WO 2008050162 A1 WO2008050162 A1 WO 2008050162A1 HU 2007000096 W HU2007000096 W HU 2007000096W WO 2008050162 A1 WO2008050162 A1 WO 2008050162A1
Authority
WO
WIPO (PCT)
Prior art keywords
desloratadine
carbon dioxide
preparation
acetone
formula
Prior art date
Application number
PCT/HU2007/000096
Other languages
French (fr)
Inventor
Tibor Mezei
Gyula Simig
Enikö MOLNÁR
Gyula LUKÁCS
Márta PORCS-MAKKAY
Zoltán KATONA
Ferenc Bartha
Donáth Györgyi VERECZKEYNÉ
Kálmán NAGY
Original Assignee
EGIS GYÓGYSZERGYÁR Nyilvånosan Müködö Részvénytársaság
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EGIS GYÓGYSZERGYÁR Nyilvånosan Müködö Részvénytársaság filed Critical EGIS GYÓGYSZERGYÁR Nyilvånosan Müködö Részvénytársaság
Publication of WO2008050162A1 publication Critical patent/WO2008050162A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the present invention relates to a process for the preparation of desloratadine adduct formed with carbon dioxide of the formula
  • the present invention relates to an improved process for the preparation of desloratadine adduct formed with carbon dioxide of the formula (I), wherein acetone is used as reaction medium.
  • the desloratadine adduct formed with carbon dioxide of the formula (I) prepared according to the present invention has good long term stability and is useful for the preparation of a stable pharmaceutical composition.
  • Desloratadine of the formula 8-chloro-6,l 1-dihydro-l 1 -(4- piperilydene)-5H-benzo[5,6]cyclohepta[1.2-b]pyridine (I) is prepared from 8-chloro-6,l 1-dihydro-l 1 -(I -ethoxy-carbonyl-4- piperilydene)-5H-benzo[5,6]cyclohepta[ 1 ,2-b]pyridine of the formula (III) by basic or acidic hydrolysis and decarboxylation.
  • Desloratadine of the formula (II) is used as a base or in salt form for the preparation of pharmaceutical compositions.
  • Two known polymorph forms and the amorphous form of desloratadine are known in the literature.
  • Inventors of the US patent application No. US 2004/0242619 describe the polymorph forms 1, 2 and the mixtures thereof.
  • Inventors of the US patent application No. US 2006/0135547 describe the preparation of the polymorphous formula 2 using a different solvent.
  • desloratadine salts can be prepared with hydrochloric acid, methane sulphonic acid, sulphuric acid, acetic acid, maleic acid, fumaric acid and phosphoric acid, the process for the preparation of these salts is not disclosed.
  • Salts of desloratadine formed with one mole acid are prepared by reacting desloratadine base with hydrochloric acid, benzene sulphonic acid, methane sulphonic acid, fumaric acid and tartaric acid in a medium containing dichloromethane.
  • the desloratadine adduct called as desloratadine pseudopolymorph of the formula (I) is described first in the international patent application No. W02006/003479.
  • the advantages of adduct make this product better than other salts for the preparation of different pharmaceutical compositions, e.g. tablets or other forms.
  • an adduct precipitates containing 1/2 mole of carbon dioxide with 1 mole desloratadine according to the formula (I.) by adding carbon dioxide into the solution of desloratadine base in tetrahydrofurane or ethyl acetate.
  • This adduct is a new pseudopolymorph form of desloratadine with half a mole of carbon dioxide.
  • the preparation of the adduct of the formula (I) is carried out in a mixture of an ester type solvent, preferably in ethyl acetate or in an ether type solvent, e.g. tetrahydrofurane or diethyl ether and a CpC 4 alcohol, preferably ethanol or methanol.
  • an ester type solvent preferably in ethyl acetate or in an ether type solvent, e.g. tetrahydrofurane or diethyl ether and a CpC 4 alcohol, preferably ethanol or methanol.
  • the product according to the formula (I) is practically insoluble in the reaction mixture containing ethyl acetate and approx. 10 % of alcohol, therefore the yield of the product is high.
  • the media containing ethyl acetate is especially preferable for the preparation of the adduct of the formula (I).
  • the adduct of the formula (I) prepared from a medium containing ethyl acetate contains ethyl acetate as contaminant evidently.
  • the preparation of the compound of the formula (I) can not be carried out in industrial scale in an appropriate quality.
  • the purpose of present invention is to work out a new process for the preparation of the adduct of desloratadine of the formula (I) which allows the preparation of the adduct of the formula (I) in industrial scale having a purity and stability appropriate for the requirements of pharmaceutical industry.
  • the present invention relates to a new process for the preparation of desloratadine adduct with carbon dioxide according to the formula (I) 5 in which acetone or a mixture of acetone and aliphatic alcohols is used as reaction medium resulting a product which is suitable for the preparation of pharmaceutical compositions acceptable by pharmaceutical authorities.
  • acetone as dipolar aprotic solvent having a high dielectric constant (20,7) is especially useful for the preparation of the adduct of desloratadine with carbon dioxide of the formula (I).
  • the thus obtained pharmaceutical active ingredient is appropriate for the preparation of a pharmaceutical composition.
  • the ester type solvents found to be advantageous e.g. ethyl acetate, butyl acetate
  • the ether type solvents e.g. diethyl ether or tetrahydrofurane
  • the basis of the present invention for the preparation of the pseudopolymorph of desloratadine of the formula (I) is the reaction of desloratadine base of the formula (II) with carbon dioxide in the presence of acetone.
  • Desloratadine base is added to the reaction mixture in a finely powdered form or in a solution of the base in alcohol.
  • the desloratadine base is dissolved in a C 1 -C 4 alcohol or in a mixture thereof, preferably dissolved in ethanol and added to the acetone, in which carbon dioxide gas is added continuously.
  • the proportion alcohol used is 3-20 % by volume preferably 5-20 % by volume, most preferably 5-17 % by volume based on the amount of used acetone.
  • carbon dioxide or dry ice is added into a suspension of desloratadine base of the formula (II) formed in acetone or in a mixture of acetone and alcohol.
  • the reaction can be carried out between 20-60 0 C.
  • the shape of the crystallines highly depends on the used reaction temperature. The shape of crystallines influences the drying properties and the amount of the remained solvent content of the product.
  • the preferred reaction temperature is between 40-55 0 C, more preferably is between 45-55 0 C, because in this case the adduct of the formula (I) precipitates from the reaction mixture in a form having good drying properties.
  • the process according to the present invention is carried out in the presence of an amount of 2-20 times volume acetone, preferably in 10-20 times volume acetone based on the weight of the used desloratadine base.
  • the X-ray diffractogram of the product prepared according to the present invention is identical to that of the adduct product which was produced according to the description of the international patent application No. W02006/003479.
  • a further object of the present invention is a process for the preparation of desloratadine of the formula (II) and acid addition salts thereof in a high purity using the adduct of desloratadine with carbon dioxide as starting material.
  • desloratadine of the formula (II) is prepared by heating or if necessary boiling a mixture of the adduct of desloratadine with 1 A mole of carbon dioxide with an organic solvent or a mixture of organic solvents, then the organic solvent is removed partly or fully forming the reaction mixture and the thus obtained desloratadine is crystallised.
  • the obtained raw desloratadine base can be recrystallised.
  • desloratadine of the formula (II) can be prepared by dissolution of the adduct of desloratadine with /4 mole of carbon dioxide in an aliphatic alcohol, then the solution is heated at its boiling point, boiled for 0.5-3 hours if necessary, then the organic solvent is evaporated and the residue is recrystallised from a mixture of acetone and methanol.
  • the obtained desloratadine base is free from hardly removable contaminants.
  • Salts of desloratadine are prepared according to processes described in the international patent application No. WO2006/003479 with the proviso that the adduct of the desloratadine with !4 mole of carbon dioxide prepared in the presence of acetone according to the present invention.
  • the adduct is dissolved in an organic solvent then reacted with a solution of the appropriate acid in an organic solvent.
  • an acid e.g. hydrochloric acid, hydrogen bromide, sulphuric acid, methane sulphonic acid, benzene sulphonic acid, maleic acid or fumaric acid can be used.
  • the acid is used in an approx. equimolar amount based on the amount of the adduct of the formula (I).
  • the salt obtained contains 1 mole of acid based on 1 mole of desloratadine.
  • the acid is used in a 2:1 molar equivalent amount, preferably in a 2:1-3:1 molar equivalent amount based on the amount of the adduct of the formula (I).
  • the salt obtained contains 2 moles of acid based on 1 mole of desloratadine.
  • the advantage of the process of the present invention is that the stable adduct of the formula (I) can be prepared in a pharmaceutically acceptable purity.
  • the drying of the product does not require such circumstances which change the stoichiometric composition of the product.
  • Acetone as residual solvent does not cause formation of contaminants even during a long storage time.
  • the adduct of desloratadine with 1 A mole of carbon dioxide is extremely suitable for the preparation of desloratadine of the formula (II) and salts thereof in high purity.
  • the reason is that the pseudopolymorph form of desloratadine of the formula (I) can be prepared in such a high purity, which is acceptable for pharmaceutical use without further purification.
  • the separation of the adduct of the formula (I) is a much more efficient purification process than the recrystallisation of the desloratadine base.
  • the reason of this fact is that the basic contaminants formed in a small amount during the removal of ethoxycarbonyl group in course the preparation of desloratadine from loratadine do not react with carbon dioxide. Therefore these contaminants remain in the mother liquor during filtering off the obtained adduct of desloratadine with 1 A mole of carbon dioxide.
  • desloratadine can be purified easily from amine type contaminants.
  • Example 1 Further details of the present invention are to be found in the following Examples without limiting the scope of protection to said Examples.
  • Example 1
  • Dry ice is placed into a 250 ml round flask, the evolved carbon dioxide is added continuously under the fluid level into an apparatus, in which 1200 ml of acetone is stirred vigorously at 45 0 C.
  • a solution of 80 g of desloratadine in 140 ml of ethanol is added dropwise during 30 minutes.
  • IR spectra and powder X-ray diffractogram are identical to the IR spectra and X-ray diffractogram of the product prepared according to the process described in international patent application No. WO2006/003479;
  • Dry ice is placed in a 50 ml round flask and the evolved carbon dioxide is added continuously under the fluid level into an apparatus, in which 120 ml of acetone is stirred vigorously at 4O 0 C.
  • a solution of 8.0 g of desloratadine in 10 ml of methanol is added dropwise to the acetone during 30 minutes.
  • IR spectra and powder X-ray diffractogram are identical to the IR spectra and X-ray diffractogram of the product prepared according to the process described in international patent application No. WO2006/003479.
  • IR spectra and powder X-ray diffractogram are identical to the IR spectra and X-ray diffractogram of the product prepared according to the process described in international patent application No. WO2006/003479.
  • Example 4
  • IR spectra and powder X-ray diffractogram are identical to the IR spectra and X-ray diffractogram of the product prepared according to the process described in international patent application No. WO2006/003479.
  • Dry ice is placed in a 50 ml round flask and the evaporated carbon dioxide is added continuously under the fluid level into an equipment in which 150 ml of acetone is stirred vigorously at 5O 0 C.
  • 8.0 g of finely powdered desloratadine is added to the acetone.
  • the suspension is stirred for two hours after the addition, then boiled for an hour.
  • the crystal suspension is cooled to 20 0 C during one hour.
  • the suspension is stirred for an hour at 5 0 C, then the precipitated product is filtered, the filter cake is washed with 15 ml of acetone of 5 0 C and dried at 40-45 0 C for 1 hour.
  • IR spectra and powder X-ray diffractogram are identical to the IR spectra and X-ray diffractogram of the product prepared according to the process described in international patent application No. WO2006/003479.
  • the product is dried at 5O 0 C for two hours, until weight uniformity.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Process for the preparation of a desloratadine adduct forme with carbon dioxide of the formula: (I)

Description

Process for the preparation of desloratadine adduct formed with carbon dioxide
FIELD OF THE INVENTION
The present invention relates to a process for the preparation of desloratadine adduct formed with carbon dioxide of the formula
Figure imgf000002_0001
Particularly, the present invention relates to an improved process for the preparation of desloratadine adduct formed with carbon dioxide of the formula (I), wherein acetone is used as reaction medium. The desloratadine adduct formed with carbon dioxide of the formula (I) prepared according to the present invention has good long term stability and is useful for the preparation of a stable pharmaceutical composition. TECHNICAL BACKGROUND OF THE INVENTION
8-chloro-6;i 1-dihydro-l l-(4-piperylydene)-5H- benzo[5,6]cyclohepta[1.2-b]pyridine (INN name: desloratadine) of the formula
Figure imgf000003_0001
II. is a known antihistamine drug, which is an active metabolite of the compound 8-chloro-6, 11-dihydro-l 1 -(I -ethoxy-carbonyl-4- piperylydene)-5H-benzo[5,6]cyclohepta[l .2-b]pyridine (INN name: loratadine) of the formula
Figure imgf000004_0001
In case of oral use of desloratadine the anti-allergic effect is 3 or 4 times higher than the effect of loratadine and the duration of the effect is almost 24 hours, which is advantageous in case of once a daily use [Arzneim. Forch. Drug. Res. 40(1), Nr. 4: 345 (2000)].
Desloratadine of the formula 8-chloro-6,l 1-dihydro-l 1 -(4- piperilydene)-5H-benzo[5,6]cyclohepta[1.2-b]pyridine (I) is prepared from 8-chloro-6,l 1-dihydro-l 1 -(I -ethoxy-carbonyl-4- piperilydene)-5H-benzo[5,6]cyclohepta[ 1 ,2-b]pyridine of the formula (III) by basic or acidic hydrolysis and decarboxylation.
Desloratadine of the formula (II) is used as a base or in salt form for the preparation of pharmaceutical compositions. Two known polymorph forms and the amorphous form of desloratadine are known in the literature. Inventors of the US patent application No. US 2004/0242619 describe the polymorph forms 1, 2 and the mixtures thereof. Inventors of the US patent application No. US 2006/0135547 describe the preparation of the polymorphous formula 2 using a different solvent.
According to the international patent application No. WO 2005/084674 an amorphous form of desloratadine is prepared by spray-drying method.
Although in the description of the Hungarian patent No. 194 864 it is mentioned that desloratadine salts can be prepared with hydrochloric acid, methane sulphonic acid, sulphuric acid, acetic acid, maleic acid, fumaric acid and phosphoric acid, the process for the preparation of these salts is not disclosed.
Some of above-mentioned salts and preparation thereof are described in the description of Hungarian patent application No. P0004701. The ethoxycarbonyl group of loratadine is eliminated by hydrolysis with mineral acids at high temperature. Salts of desloratadine with two moles of the acid (1:2 salts) can be isolated directly from the reaction mixture. Preparation of desloratadine disulphate, dihydrochloride, dihydrobromide salts is shown. Among the examples the process for the preparation of hemisulphate salt of desloratadine from disulphate salt is also described. Salts of desloratadine formed with one mole acid (1:1 salts) are prepared by reacting desloratadine base with hydrochloric acid, benzene sulphonic acid, methane sulphonic acid, fumaric acid and tartaric acid in a medium containing dichloromethane.
Two polymorphs of desloratadine hemifumarate are described in international PCT patent application No. 2004/012738. The difference between the melting points of these polymorphs is some degrees of Celsius.
The desloratadine adduct called as desloratadine pseudopolymorph of the formula (I) is described first in the international patent application No. W02006/003479. The advantages of adduct make this product better than other salts for the preparation of different pharmaceutical compositions, e.g. tablets or other forms. According to the description of said patent application an adduct precipitates containing 1/2 mole of carbon dioxide with 1 mole desloratadine according to the formula (I.) by adding carbon dioxide into the solution of desloratadine base in tetrahydrofurane or ethyl acetate.
This adduct is a new pseudopolymorph form of desloratadine with half a mole of carbon dioxide.
According to the results of HPLC examinations this adduct of the formula (I) has a very high purity.
The reason of the high purity is that the contaminants having basic properties in the solution containing raw desloratadine base do not produce adducts, therefore these contaminants remain in the solution, meanwhile the only crystallised product is the adduct of desloratadine.
According to the international patent application No. W02006/003479 the preparation of the adduct of the formula (I) is carried out in a mixture of an ester type solvent, preferably in ethyl acetate or in an ether type solvent, e.g. tetrahydrofurane or diethyl ether and a CpC4 alcohol, preferably ethanol or methanol. If carbon dioxide is added into a solution of desloratadine base in an organic solvent or desloratadine is added to an organic solvent, meanwhile carbon dioxide is added into the mixture, a product having appropriate carbon dioxide content can be prepared. Solubility of desloratadine base in ether or ester type solvents is relative low, in methanol or ethanol is good, therefore according to the preferable embodiment of the process a solution of desloratadine in alcohol is added to the reaction mixture.
The product according to the formula (I) is practically insoluble in the reaction mixture containing ethyl acetate and approx. 10 % of alcohol, therefore the yield of the product is high. According to the description of international patent application No. W02006/003479 the media containing ethyl acetate is especially preferable for the preparation of the adduct of the formula (I).
The adduct of the formula (I) prepared from a medium containing ethyl acetate contains ethyl acetate as contaminant evidently.
In case of reproduction of the preparation of the product according to the patent application No. W02006/003479 in laboratory scale the amount of this contaminant is lower than the amount allowed by pharmacopoeias, but an unexpected problem appears during the examination of the pharmaceutical composition prepared from the product contaminated by this contaminant. During the storage of the pharmaceutical composition containing active ingredients having an ester type contaminant, N-acetyl-desloratadine according to the formula
Figure imgf000009_0001
is formed and the amount of this contaminant increases to a higher level than allowed by pharmaceutical authorities.
Scaling up the processes described in the patent application No. W02006/003479 in case of using other solvents, e.g. tetrahydroforane or diethyl ether entails further difficulties. The elimination of the residual solvents in industrial scale to the level required by authorities can only be achieved by using elevated temperature and vacuum simultaneously, which destructs the stoichiometric composition of the product.
Based on the facts above, the preparation of the compound of the formula (I) can not be carried out in industrial scale in an appropriate quality. The purpose of present invention is to work out a new process for the preparation of the adduct of desloratadine of the formula (I) which allows the preparation of the adduct of the formula (I) in industrial scale having a purity and stability appropriate for the requirements of pharmaceutical industry.
SUMMARY OF THE INVENTION
The present invention relates to a new process for the preparation of desloratadine adduct with carbon dioxide according to the formula (I)5 in which acetone or a mixture of acetone and aliphatic alcohols is used as reaction medium resulting a product which is suitable for the preparation of pharmaceutical compositions acceptable by pharmaceutical authorities.
DETAILED DESCRIPTION OF THE INVENTION
We found surprisingly, that acetone as dipolar aprotic solvent having a high dielectric constant (20,7) is especially useful for the preparation of the adduct of desloratadine with carbon dioxide of the formula (I). The thus obtained pharmaceutical active ingredient is appropriate for the preparation of a pharmaceutical composition. AU the more surprising that the use of acetone having a high dielectric constant (20,7) is favourable for the preparation of the adduct of the formula (I) because the ester type solvents found to be advantageous (e.g. ethyl acetate, butyl acetate) and the ether type solvents (e.g. diethyl ether or tetrahydrofurane) used according to the international patent application No. W02006/003479 are apolar solvents having low dielectric constants of approximately 4-6.
Although we have found that the adduct is not formed in alcohols having a high dielectric constant (over 20), moreover, in the case when the adduct was added into alcohol, its destruction was detected with the evolution of carbon dioxide gas, the use of small amount of alcohol (max. 15% by volume) in the reaction mixture is acceptable.
The polarities of different materials including solvents are characterized with their dielectric constants, which can be found in different chemical handbooks, e.g. on pages of E-49- 52 of the issue 64 of CRC Handbook of Chemistry and Physics.
The basis of the present invention for the preparation of the pseudopolymorph of desloratadine of the formula (I) is the reaction of desloratadine base of the formula (II) with carbon dioxide in the presence of acetone.
Desloratadine base is added to the reaction mixture in a finely powdered form or in a solution of the base in alcohol.
According to the advantageous embodiment of the present invention the desloratadine base is dissolved in a C1-C4 alcohol or in a mixture thereof, preferably dissolved in ethanol and added to the acetone, in which carbon dioxide gas is added continuously. The proportion alcohol used is 3-20 % by volume preferably 5-20 % by volume, most preferably 5-17 % by volume based on the amount of used acetone.
According to another embodiment of the present invention carbon dioxide or dry ice is added into a suspension of desloratadine base of the formula (II) formed in acetone or in a mixture of acetone and alcohol.
The reaction can be carried out between 20-600C. The shape of the crystallines highly depends on the used reaction temperature. The shape of crystallines influences the drying properties and the amount of the remained solvent content of the product. The preferred reaction temperature is between 40-550C, more preferably is between 45-550C, because in this case the adduct of the formula (I) precipitates from the reaction mixture in a form having good drying properties.
The process according to the present invention is carried out in the presence of an amount of 2-20 times volume acetone, preferably in 10-20 times volume acetone based on the weight of the used desloratadine base.
The X-ray diffractogram of the product prepared according to the present invention is identical to that of the adduct product which was produced according to the description of the international patent application No. W02006/003479.
A further object of the present invention is a process for the preparation of desloratadine of the formula (II) and acid addition salts thereof in a high purity using the adduct of desloratadine with carbon dioxide as starting material.
Particularly, desloratadine of the formula (II) is prepared by heating or if necessary boiling a mixture of the adduct of desloratadine with 1A mole of carbon dioxide with an organic solvent or a mixture of organic solvents, then the organic solvent is removed partly or fully forming the reaction mixture and the thus obtained desloratadine is crystallised. The obtained raw desloratadine base can be recrystallised.
According to a preferable embodiment of the present invention, desloratadine of the formula (II) can be prepared by dissolution of the adduct of desloratadine with /4 mole of carbon dioxide in an aliphatic alcohol, then the solution is heated at its boiling point, boiled for 0.5-3 hours if necessary, then the organic solvent is evaporated and the residue is recrystallised from a mixture of acetone and methanol.
The different polymorph forms of desloratadine known from the literature can be prepared using specific circumstances and solvents of the recrystallisation process.
Taking into consideration that the amine type side products have been eliminated in course of the preparation of the adduct of the desloratadine with 1A mole of carbon dioxide, the obtained desloratadine base is free from hardly removable contaminants.
Salts of desloratadine are prepared according to processes described in the international patent application No. WO2006/003479 with the proviso that the adduct of the desloratadine with !4 mole of carbon dioxide prepared in the presence of acetone according to the present invention. The adduct is dissolved in an organic solvent then reacted with a solution of the appropriate acid in an organic solvent.
As an acid e.g. hydrochloric acid, hydrogen bromide, sulphuric acid, methane sulphonic acid, benzene sulphonic acid, maleic acid or fumaric acid can be used.
According to an embodiment of the present invention the acid is used in an approx. equimolar amount based on the amount of the adduct of the formula (I). In this case the salt obtained contains 1 mole of acid based on 1 mole of desloratadine.
According to another embodiment of the present invention the acid is used in a 2:1 molar equivalent amount, preferably in a 2:1-3:1 molar equivalent amount based on the amount of the adduct of the formula (I). In this case the salt obtained contains 2 moles of acid based on 1 mole of desloratadine.
The advantage of the process of the present invention is that the stable adduct of the formula (I) can be prepared in a pharmaceutically acceptable purity. The drying of the product does not require such circumstances which change the stoichiometric composition of the product. Acetone as residual solvent does not cause formation of contaminants even during a long storage time.
Other advantage of the present invention is that the adduct of desloratadine with 1A mole of carbon dioxide is extremely suitable for the preparation of desloratadine of the formula (II) and salts thereof in high purity. The reason is that the pseudopolymorph form of desloratadine of the formula (I) can be prepared in such a high purity, which is acceptable for pharmaceutical use without further purification. The separation of the adduct of the formula (I) is a much more efficient purification process than the recrystallisation of the desloratadine base. The reason of this fact is that the basic contaminants formed in a small amount during the removal of ethoxycarbonyl group in course the preparation of desloratadine from loratadine do not react with carbon dioxide. Therefore these contaminants remain in the mother liquor during filtering off the obtained adduct of desloratadine with 1A mole of carbon dioxide. Thus, desloratadine can be purified easily from amine type contaminants.
Further details of the present invention are to be found in the following Examples without limiting the scope of protection to said Examples. Example 1
Preparation of adduct of desloratadine with half a mole of carbon dioxide (I)
Dry ice is placed into a 250 ml round flask, the evolved carbon dioxide is added continuously under the fluid level into an apparatus, in which 1200 ml of acetone is stirred vigorously at 450C. A solution of 80 g of desloratadine in 140 ml of ethanol is added dropwise during 30 minutes.
After adding of approx. the half of the desloratadine solution crystallisation of the product begins. The crystal suspension is cooled to 20 0C during one hour. The suspension is stirred for an hour at 5 0C5 then the precipitated product is filtered, the filter cake is washed with 150 ml of acetone of 5 0C and dried at 250C for 2-3 hours until weight uniformity.
Yield: 80.7 g (94.3 %) white powder.
Analysis: Ci9H19ClN2 x 1A CO2 (332.87) Calculated: C:70.71 H:5.79 Cl:10.62 N:8.41
Found: C:70 .85 H:5 .66 Cl: 10 .81 N.-8.383
IR spectra and powder X-ray diffractogram are identical to the IR spectra and X-ray diffractogram of the product prepared according to the process described in international patent application No. WO2006/003479;
Example 2
Preparation of pseudopolymorph of desloratadirie with half a mole of carbon dioxide (I)
Dry ice is placed in a 50 ml round flask and the evolved carbon dioxide is added continuously under the fluid level into an apparatus, in which 120 ml of acetone is stirred vigorously at 4O0C. A solution of 8.0 g of desloratadine in 10 ml of methanol is added dropwise to the acetone during 30 minutes.
After adding of approx. the half of the desloratadine solution crystallisation of the product begins. The crystal suspension is cooled to 20 0C during one hour. The suspension is stirred for an hour at 5 0C, then the precipitated product is filtered, the filter cake is washed with 15 ml of acetone of 5 0C and dried at 450C for 3 hours. Yield: 8.26 g (96.0 %) white powder.
IR spectra and powder X-ray diffractogram are identical to the IR spectra and X-ray diffractogram of the product prepared according to the process described in international patent application No. WO2006/003479.
Example 3
Preparation of pseudopolymorph of desloratadine with half a mole of carbon dioxide (I).
The reaction is carried out according to Example 2 with the proviso that desloratadine base is dissolved in 20 ml of 2- propanol having a temperature of 6O0C and the solution is added to acetone of 55 0C .
Yield: 8.20 g (95.2 %) white powder.
IR spectra and powder X-ray diffractogram are identical to the IR spectra and X-ray diffractogram of the product prepared according to the process described in international patent application No. WO2006/003479. Example 4
Preparation of pseudopolymorph of desloratadine with half a mole of carbon dioxide (I).
The reaction is carried out according to Example 2 with the proviso that desloratadine base is dissolved in 20 ml of 1- butanol of 6O0C and the solution of desloratadine base in 1- butanol is added to acetone of 50 0C.
Yield: 8.12 g (94.3 %) white powder.
IR spectra and powder X-ray diffractogram are identical to the IR spectra and X-ray diffractogram of the product prepared according to the process described in international patent application No. WO2006/003479.
Example 5
Preparation of pseudopolymorph of desloratadine with half a mole of carbon dioxide (I)
Dry ice is placed in a 50 ml round flask and the evaporated carbon dioxide is added continuously under the fluid level into an equipment in which 150 ml of acetone is stirred vigorously at 5O0C. In small portions 8.0 g of finely powdered desloratadine is added to the acetone. The suspension is stirred for two hours after the addition, then boiled for an hour. The crystal suspension is cooled to 20 0C during one hour. The suspension is stirred for an hour at 5 0C, then the precipitated product is filtered, the filter cake is washed with 15 ml of acetone of 5 0C and dried at 40-450C for 1 hour.
Yield: 8.37 g (97.5 %) white powder.
IR spectra and powder X-ray diffractogram are identical to the IR spectra and X-ray diffractogram of the product prepared according to the process described in international patent application No. WO2006/003479.
Example 6
Polymorph form 1 of desloratadine base
In 120 ml of ethanol 40 g of adduct of desloratadine with Vi mole of carbon dioxide is boiled for an hour, then the solvent is evaporated. 360 ml of acetone and 20 ml of methanol are added to the warm residue. The mixture is boiled and decolourised with carbon, filtered, the filtrate is left to cool to 25 0C during half an hour and stirred for an additional hour. The crystal suspension is stirred at -1O0C for four hours, then filtered.
The product is dried at 5O0C for two hours, until weight uniformity.
Yield: 23.5 g (63.0 %) Melting point: 257-2580C
Based on the IR spectra and powder X-ray diffractogram the product is pure desloratadine base of the polymorph form 1.
Example 7
Preparation of desloratadine hydrochloride (1 :1) from the carbon dioxide pseudopolymorph of desloratadine formed with half a mole of carbon dioxide
To a suspension of 7.1 g (20 mmoles) of the carbon dioxide adduct of desloratadine in 100 ml ethyl acetate, a solution of 0.73 g (20 mmoles) of hydrogen chloride in ethyl acetate is added at 20-25 0C within 10 minutes. The suspension is stirred for 3 hours until the gas evolution is finished, then cooled to 0 0C, filtered, and the crystals are washed with ethanol. Yield: 6.61 g (95.2 %) white crystals.
Mp.: 261-263 0C
Analysis: for the formula of C19H19ClN2 * HCl (347.29)
Calculated: C:65.71 H:5.80 Cl:20.42 N:8.07
Found: C:65.39 H:5.75 Cl:20.26 N:8.02
HPLC purity >99.8 %

Claims

What we claim is,
1. Process for the preparation of the pseudopolymorph of desloratadine of the formula
Figure imgf000024_0001
I. .
characterized in that desloratadine base of the formula
Figure imgf000024_0002
II.
is reacted with carbon dioxide in the presence of acetone.
2. Process according to Claim 1 characterized in that the desloratadine base is added dissolved in alcohol or in a powdered form to the acetone.
3. Process according to Claims 1 or 2 characterized in that C1-C4 alcohols, preferably ethanol are used to dissolution of desloratadine base.
4. Process according to Claims 2 or 3 characterized in that the volume of alcohol used for the dissolution of desloratadine base is 3-20%, preferably 5-20%, more preferably 5-17% by volume of used acetone.
5. Process according to any of Claims 1-4 characterized in that the reaction is carried out between 20-600C, preferably between 40-550C, more preferably between
45-550C.
6. Process according to any of Claims 1-5 characterized in that the reaction is carried out in acetone of 2-50 times volume, preferably 10-20 times volume based on the weight of desloratadine base.
7. Process according to any of Claims 1-6 characterized in that carbon dioxide gas or dry ice is added to a solution of desloratadine base in acetone.
8. Process for the preparation of desloratadine, characterized in that the adduct of desloratadine prepared according to any of the claims 1-7 is heated in an organic solvent, then evaporated and recrystallised if necessary.
9. Process for the preparation of polymorph form 1 of desloratadine characterized in that the adduct of desloratadine with Vi of carbon dioxide of the formula (I) is boiled in ethanol then evaporated in vacuum, the residue is recrystallised from a mixture of acetone and methanol, then filtered and dried.
10. Process for the preparation of acid addition salts of desloratadine characterized in that the solution of pseudopolymorph form of desloratadine with carbon dioxide prepared according to Claims 1-7 in an organic solution is reacted with a solution of the appropriate acid in an organic solvent.
PCT/HU2007/000096 2006-10-26 2007-10-25 Process for the preparation of desloratadine adduct formed with carbon dioxide WO2008050162A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0600805A HU230417B1 (en) 2006-10-26 2006-10-26 Process for producing adduct comprising desloratadine and carbon dioxide
HUP0600805 2006-10-26

Publications (1)

Publication Number Publication Date
WO2008050162A1 true WO2008050162A1 (en) 2008-05-02

Family

ID=89987102

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU2007/000096 WO2008050162A1 (en) 2006-10-26 2007-10-25 Process for the preparation of desloratadine adduct formed with carbon dioxide

Country Status (2)

Country Link
HU (1) HU230417B1 (en)
WO (1) WO2008050162A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985003707A1 (en) * 1984-02-15 1985-08-29 Schering Corporation 8-CHLORO-6,11-DIHYDRO-11-(4-PIPERIDYLIDENE)-5H-BENZO AD5,6 BDCYCLOHEPTA AD1,2-b BDPYRIDINE AND ITS SALTS, PROCESSES FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS
WO1999001450A1 (en) * 1997-07-02 1999-01-14 Schering Corporation POLYMORPHS OF 8-CHLORO-6, 11-DIHYDRO-11- (4-PIPERIDYLIDENE) -5H-BENZO[5,6] CYCLOHEPTA[1,2-b]PYRIDINE
WO2006003479A2 (en) * 2004-07-07 2006-01-12 EGIS Gyógyszergyár Rt. New pseudopolymorph of desloratadine formed with carbon dioxide

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985003707A1 (en) * 1984-02-15 1985-08-29 Schering Corporation 8-CHLORO-6,11-DIHYDRO-11-(4-PIPERIDYLIDENE)-5H-BENZO AD5,6 BDCYCLOHEPTA AD1,2-b BDPYRIDINE AND ITS SALTS, PROCESSES FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS
WO1999001450A1 (en) * 1997-07-02 1999-01-14 Schering Corporation POLYMORPHS OF 8-CHLORO-6, 11-DIHYDRO-11- (4-PIPERIDYLIDENE) -5H-BENZO[5,6] CYCLOHEPTA[1,2-b]PYRIDINE
WO2006003479A2 (en) * 2004-07-07 2006-01-12 EGIS Gyógyszergyár Rt. New pseudopolymorph of desloratadine formed with carbon dioxide

Also Published As

Publication number Publication date
HU230417B1 (en) 2016-05-30
HU0600805D0 (en) 2006-12-28
HUP0600805A2 (en) 2008-05-28

Similar Documents

Publication Publication Date Title
AU2005289099B2 (en) Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide
JP5656952B2 (en) Piperazine derivative oxalate crystals
US20040167157A1 (en) Process for preparation of amidine derivatives
US20210292276A1 (en) Polymorphic forms of belinostat and processes for preparation thereof
EP2409967A1 (en) Polymorphs of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
EP2598499A2 (en) Process for the preparation of imatinib mesylate
JPH11508601A (en) Aminate compounds and their production process
JP2002528436A (en) Intermediates for the synthesis of amlodipine, their preparation and use
EP1674463A1 (en) Rabeprazole sodium salt in crystalline hydrate form
EP2608791B1 (en) A process for the preparation of imatinib base
CN115427403A (en) Synthesis of monoacylglycerol lipase inhibitors
EP1935891A1 (en) Crystalline forms of rabeprazole sodium
RU2679636C1 (en) New method of the n,n'-bis[2-(1h-imidazol-4-yl)ethyl]malonamide obtaining
EP1817307A2 (en) New pseudopolymorph of desloratadine formed with carbon dioxide
WO2008050162A1 (en) Process for the preparation of desloratadine adduct formed with carbon dioxide
SI21850A (en) Salts of olanzapin and their transformation into free base of olanzapin
CA2504796A1 (en) Polymorphs of pantoprazole sodium salt and process for the preparation thereof
EP1485373A1 (en) Method of stabilizing lansoprazole
KR101752449B1 (en) Manufacturing process of solifenacin or solifenacin salt, the new intermediate in the process and manufacturing process therof
CA2436265A1 (en) 3-(3-amidinophenyl)-5-[({[1-(1-iminoethyl)-4-piperidyl]methyl}amino)methyl]benzoic acid dihydrochloride and process for preparing the same
JP2011195500A (en) Method for producing (s)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butanoic acid/benzenesulfonic acid salt
JP2010105935A (en) METHOD FOR PURIFYING 4-(8-CHLORO-5,6-DIHYDRO-11H-BENZO[5,6]CYCLOHEPTA[1,2-b]PYRIDIN-11-YLIDENE)-1-PIPERIDINECARBOXYLIC ACID ETHYL ESTER
EP1686126A1 (en) Salts of aripiprazole
WO2022271109A1 (en) New polymorph of vismodegib and method for its preparation
CA3214107A1 (en) New process for the synthesis of 5-{5-chloro-2-[(3s)-3- [(morpholin-4-yl)methyl]-3,4-dihydroisoquinoline-2(1h)- carbonyl]phenyl}-1,2-dimethyl-1h-pyrrole-3-carboxylic acid derivatives and its application for the production of pharmaceutical compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07824988

Country of ref document: EP

Kind code of ref document: A1

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07824988

Country of ref document: EP

Kind code of ref document: A1